A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.

Jennifer R DiamondS G EckhardtTodd M PittsAdrie van BokhovenDara AisnerDaniel L GustafsonAnna CapassoSharon SamsPeter KabosKathryn ZolmanTiffany ColvinAnthony D EliasAnna M StornioloBryan P SchneiderDexiang GaoJohn J TentlerVirginia F BorgesKathy D Miller

Published in: Breast cancer research : BCR (2018)

ClinicalTrials.gov, NCT01639248 . Registered on July 12, 2012.

Keyphrases

phase ii
clinical trial
open label
squamous cell carcinoma
small cell lung cancer
double blind
phase iii